Standardized SEC financial data for ALBIREO PHARMA, INC. — income statement, balance sheet, cash flow and 40+ ratios, available as a clean JSON API. CIK 0001322505 · Pharmaceutical Preparations.
Ratios for fiscal year 2021, standardized from SEC filings.
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | $11.4M | $1K | $12.7M | $9.6M | $8.3M | $40.6M |
| Cost of revenue | — | — | — | — | — | $1.4M |
| Gross profit | — | — | — | — |
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $29.9M | $53.2M | $163.9M | $131.8M | $251.3M | $248.1M |
| Inventory | — | — | — | — | — | $194K |
| Total current assets | $30.9M | $55.0M | $167.7M | $141.8M | $261.9M |
| USD | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$8.8M | -$27.6M | -$26.8M | -$52.9M | -$101.0M | -$107.6M |
| Capital expenditures | $3K | $190K | $61K | $540K | $78K | $465K |
| Free cash flow | -$8.8M | -$27.8M | -$26.9M | -$53.5M |
# JSON
curl https://sec-financial-api-production.up.railway.app/v1/company/0001322505/financials \
-H "X-API-Key: YOUR_KEY"
# CSV export (income / balance / cash-flow)
curl "https://sec-financial-api-production.up.railway.app/v1/company/0001322505/income-statement?format=csv" \
-H "X-API-Key: YOUR_KEY"| $8.3M |
| $39.2M |
| R&D expense | $8.1M | $13.0M | $31.7M | $45.6M | $76.8M | $82.5M |
| SG&A expense | $15.8M | $15.2M | $18.1M | $23.0M | $42.4M | $69.6M |
| Operating income | -$12.3M | -$24.6M | -$37.9M | -$61.1M | -$96.3M | -$123.5M |
| EBITDA | -$12.3M | -$24.5M | -$37.8M | -$61.0M | -$96.1M | -$123.2M |
| Interest expense | $450K | $178K | — | — | — | — |
| Pretax income | -$16.3M | -$24.2M | -$46.1M | -$62.7M | -$107.6M | -$34.0M |
| Income tax | $62K | $212K | $20K | — | — | — |
| Net income | -$16.4M | -$24.4M | -$46.1M | -$62.7M | -$107.6M | -$34.0M |
| EPS (diluted) | — | — | — | — | $-6.73 | $-1.77 |
Standardized from ALBIREO PHARMA, INC.'s SEC filings — per-share figures split-adjusted. Full history via the API.
| $268.9M |
| Property, plant & equipment | $21K | $178K | $187K | $597K | $478K | $668K |
| Goodwill | $18.1M | $17.3M | $17.3M | $17.3M | $17.3M | $17.3M |
| Total assets | $49.7M | $73.2M | $185.5M | $165.1M | $285.6M | $302.1M |
| Total current liabilities | $12.7M | $7.9M | $12.8M | $18.9M | $25.3M | $45.3M |
| Long-term debt | $3.1M | $0 | — | — | — | — |
| Total debt | $6.2M | $0 | — | — | — | — |
| Total liabilities | $12.7M | $8.0M | $62.8M | $71.9M | $104.4M | $126.4M |
| Retained earnings | -$25.9M | -$50.4M | -$96.5M | -$159.2M | -$266.8M | -$300.9M |
| Total equity | $37.0M | $65.3M | $122.6M | $93.2M | $181.2M | $175.6M |
| -$101.1M |
| -$108.0M |
| Investing cash flow | $25.5M | $4.3M | -$47K | -$540K | -$78K | $102.9M |
| Financing cash flow | $7.6M | $45.8M | $139.2M | $23.5M | $220.3M | $2.8M |
| Dividends paid | $0 | $0 | — | — | — | — |
| Share repurchases | — | — | — | — | — | $230K |